25 XP   0   0   10

Cogent Biosciences Inc
Buy, Hold or Sell?

Let's analyse Cogent Biosciences Inc together

PenkeI guess you are interested in Cogent Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cogent Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cogent Biosciences Inc

I send you an email if I find something interesting about Cogent Biosciences Inc.

Quick analysis of Cogent Biosciences Inc (30 sec.)










What can you expect buying and holding a share of Cogent Biosciences Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.48
Expected worth in 1 year
$2.50
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$0.02
Return On Investment
0.3%

For what price can you sell your share?

Current Price per Share
$6.50
Expected price per share
$4.28 - $9.23
How sure are you?
50%

1. Valuation of Cogent Biosciences Inc (5 min.)




Live pricePrice per Share (EOD)

$6.50

Intrinsic Value Per Share

$-24.10 - $-28.55

Total Value Per Share

$-21.62 - $-26.07

2. Growth of Cogent Biosciences Inc (5 min.)




Is Cogent Biosciences Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$257.8m$263.2m$19.9m7.0%

How much money is Cogent Biosciences Inc making?

Current yearPrevious yearGrowGrow %
Making money-$46.9m-$33.1m-$13.7m-29.4%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Cogent Biosciences Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#198 / 1019

Most Revenue
#984 / 1019

Most Profit
#883 / 1019

Most Efficient
#427 / 1019

What can you expect buying and holding a share of Cogent Biosciences Inc? (5 min.)

Welcome investor! Cogent Biosciences Inc's management wants to use your money to grow the business. In return you get a share of Cogent Biosciences Inc.

What can you expect buying and holding a share of Cogent Biosciences Inc?

First you should know what it really means to hold a share of Cogent Biosciences Inc. And how you can make/lose money.

Speculation

The Price per Share of Cogent Biosciences Inc is $6.5. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cogent Biosciences Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cogent Biosciences Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.48. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cogent Biosciences Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.52-8.0%-0.46-7.1%-0.34-5.2%-0.30-4.6%-0.23-3.6%
Usd Book Value Change Per Share-0.43-6.7%0.000.1%0.101.5%0.101.5%0.091.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.43-6.7%0.000.1%0.101.5%0.101.5%0.091.4%
Usd Price Per Share5.88-9.57-10.75-6.94-6.39-
Price to Earnings Ratio-2.81--5.41--7.92--6.20--8.85-
Price-to-Total Gains Ratio-13.55--15.20--27.55--21.30--28.09-
Price to Book Ratio2.37-3.57-4.28-3.49-6.62-
Price-to-Total Gains Ratio-13.55--15.20--27.55--21.30--28.09-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.5
Number of shares153
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.10
Usd Total Gains Per Share0.000.10
Gains per Quarter (153 shares)0.7614.54
Gains per Year (153 shares)3.0458.18
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
103-705848
206-40116106
309-10175164
401220233222
501550291280
601880349338
7021110407396
8024140465454
9027170524512
10030200582570

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.027.00.03.6%1.027.00.03.6%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%7.018.03.025.0%7.018.03.025.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.028.00.0%0.00.028.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%7.018.03.025.0%7.018.03.025.0%

Fundamentals of Cogent Biosciences Inc

About Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 04:42:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cogent Biosciences Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cogent Biosciences Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cogent Biosciences Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cogent Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-969.0%+969.0%
5Y-969.0%10Y-791.8%-177.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--196.9%+196.9%
TTM--211.2%+211.2%
YOY--279.3%+279.3%
5Y-969.0%-436.8%-532.2%
10Y-791.8%-599.3%-192.5%
1.1.2. Return on Assets

Shows how efficient Cogent Biosciences Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cogent Biosciences Inc to the Biotechnology industry mean.
  • -17.3% Return on Assets means that Cogent Biosciences Inc generated $-0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cogent Biosciences Inc:

  • The MRQ is -17.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -14.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.3%TTM-14.3%-3.1%
TTM-14.3%YOY-11.4%-2.9%
TTM-14.3%5Y-13.0%-1.3%
5Y-13.0%10Y-11.4%-1.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.3%-13.6%-3.7%
TTM-14.3%-12.9%-1.4%
YOY-11.4%-11.9%+0.5%
5Y-13.0%-14.2%+1.2%
10Y-11.4%-16.2%+4.8%
1.1.3. Return on Equity

Shows how efficient Cogent Biosciences Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cogent Biosciences Inc to the Biotechnology industry mean.
  • -21.1% Return on Equity means Cogent Biosciences Inc generated $-0.21 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cogent Biosciences Inc:

  • The MRQ is -21.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -16.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-21.1%TTM-16.8%-4.3%
TTM-16.8%YOY-13.0%-3.8%
TTM-16.8%5Y-15.2%-1.6%
5Y-15.2%10Y-14.7%-0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.1%-17.0%-4.1%
TTM-16.8%-16.1%-0.7%
YOY-13.0%-15.4%+2.4%
5Y-15.2%-20.0%+4.8%
10Y-14.7%-21.1%+6.4%

1.2. Operating Efficiency of Cogent Biosciences Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cogent Biosciences Inc is operating .

  • Measures how much profit Cogent Biosciences Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cogent Biosciences Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cogent Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-1,208.8%+1,208.8%
5Y-1,208.8%10Y-966.6%-242.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--282.4%+282.4%
TTM--225.8%+225.8%
YOY--288.4%+288.4%
5Y-1,208.8%-475.2%-733.6%
10Y-966.6%-624.7%-341.9%
1.2.2. Operating Ratio

Measures how efficient Cogent Biosciences Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cogent Biosciences Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y11.206-11.206
5Y11.20610Y9.322+1.884
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.994-2.994
TTM-3.247-3.247
YOY-3.766-3.766
5Y11.2065.675+5.531
10Y9.3227.857+1.465

1.3. Liquidity of Cogent Biosciences Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cogent Biosciences Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.09 means the company has $7.09 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cogent Biosciences Inc:

  • The MRQ is 7.094. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.951. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.094TTM9.951-2.857
TTM9.951YOY11.326-1.374
TTM9.9515Y9.816+0.136
5Y9.81610Y7.578+2.237
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0943.930+3.164
TTM9.9514.251+5.700
YOY11.3265.436+5.890
5Y9.8166.045+3.771
10Y7.5786.383+1.195
1.3.2. Quick Ratio

Measures if Cogent Biosciences Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cogent Biosciences Inc to the Biotechnology industry mean.
  • A Quick Ratio of 12.53 means the company can pay off $12.53 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cogent Biosciences Inc:

  • The MRQ is 12.529. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 14.707. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ12.529TTM14.707-2.179
TTM14.707YOY13.836+0.871
TTM14.7075Y11.200+3.507
5Y11.20010Y8.762+2.438
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.5293.629+8.900
TTM14.7074.065+10.642
YOY13.8365.390+8.446
5Y11.2005.993+5.207
10Y8.7626.277+2.485

1.4. Solvency of Cogent Biosciences Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cogent Biosciences Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cogent Biosciences Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.18 means that Cogent Biosciences Inc assets are financed with 17.7% credit (debt) and the remaining percentage (100% - 17.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cogent Biosciences Inc:

  • The MRQ is 0.177. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.147. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.177TTM0.147+0.031
TTM0.147YOY0.124+0.023
TTM0.1475Y0.249-0.102
5Y0.24910Y0.246+0.003
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1770.332-0.155
TTM0.1470.333-0.186
YOY0.1240.268-0.144
5Y0.2490.366-0.117
10Y0.2460.390-0.144
1.4.2. Debt to Equity Ratio

Measures if Cogent Biosciences Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cogent Biosciences Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 21.6% means that company has $0.22 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cogent Biosciences Inc:

  • The MRQ is 0.216. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.173. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.216TTM0.173+0.043
TTM0.173YOY0.142+0.031
TTM0.1735Y0.286-0.113
5Y0.28610Y0.334-0.048
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2160.380-0.164
TTM0.1730.389-0.216
YOY0.1420.334-0.192
5Y0.2860.432-0.146
10Y0.3340.465-0.131

2. Market Valuation of Cogent Biosciences Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cogent Biosciences Inc generates.

  • Above 15 is considered overpriced but always compare Cogent Biosciences Inc to the Biotechnology industry mean.
  • A PE ratio of -2.81 means the investor is paying $-2.81 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cogent Biosciences Inc:

  • The EOD is -3.106. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.810. Based on the earnings, the company is expensive. -2
  • The TTM is -5.406. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.106MRQ-2.810-0.296
MRQ-2.810TTM-5.406+2.597
TTM-5.406YOY-7.924+2.517
TTM-5.4065Y-6.203+0.797
5Y-6.20310Y-8.851+2.648
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.106-2.426-0.680
MRQ-2.810-2.552-0.258
TTM-5.406-2.656-2.750
YOY-7.924-4.143-3.781
5Y-6.203-6.252+0.049
10Y-8.851-6.108-2.743
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cogent Biosciences Inc:

  • The EOD is -3.804. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.442. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.555. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.804MRQ-3.442-0.363
MRQ-3.442TTM-6.555+3.114
TTM-6.555YOY-8.773+2.217
TTM-6.5555Y-9.288+2.732
5Y-9.28810Y-11.200+1.912
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.804-3.199-0.605
MRQ-3.442-3.259-0.183
TTM-6.555-3.552-3.003
YOY-8.773-5.617-3.156
5Y-9.288-8.326-0.962
10Y-11.200-8.689-2.511
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cogent Biosciences Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.37 means the investor is paying $2.37 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cogent Biosciences Inc:

  • The EOD is 2.620. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.370. Based on the equity, the company is underpriced. +1
  • The TTM is 3.565. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.620MRQ2.370+0.250
MRQ2.370TTM3.565-1.195
TTM3.565YOY4.281-0.715
TTM3.5655Y3.490+0.075
5Y3.49010Y6.618-3.128
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.6201.947+0.673
MRQ2.3702.116+0.254
TTM3.5652.095+1.470
YOY4.2812.836+1.445
5Y3.4903.443+0.047
10Y6.6183.791+2.827
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cogent Biosciences Inc.

3.1. Institutions holding Cogent Biosciences Inc

Institutions are holding 99.982% of the shares of Cogent Biosciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc6.50120.00167555846085069.8991
2023-12-31Kynam Capital Management, LP5.63433.81458547663644641164.9066
2023-12-31TCG Crossover Management, LLC5.4193.672563104200
2023-12-31COMMODORE CAPITAL LP5.35642.8597556602600
2023-12-31FMR Inc5.10310.0024530285473307316.0418
2023-09-30VR Adviser, LLC4.50784.80774684167350.0007
2023-12-31Vanguard Group Inc4.36390.000645346551613443.6893
2023-12-31State Street Corporation3.99430.00124150615118298039.8627
2023-09-30Point72 Asset Management, L.P.3.62490.10723766755-918299-19.6006
2023-12-31Suvretta Capital Management, LLC3.57080.9864371053965723921.5255
2023-12-31Fairmount Funds Management LLC3.42492.2111355897500
2023-12-31Millennium Management LLC2.69190.0071279724426735552161.514
2023-12-31Morgan Stanley - Brokerage Accounts2.17410.0012225920121297021644.5702
2023-12-31Vivo Capital, LLC2.16041.0808224494100
2023-12-31Eventide Asset Management, LLC2.14890.21432232968829683.859
2023-09-30Redmile Group, LLC1.9760.9525205333300
2023-12-31Geode Capital Management, LLC1.66370.00111728782815364.9498
2023-12-31Dimensional Fund Advisors, Inc.1.57520.00281636834571433.6174
2023-12-31Nantahala Capital Management, LLC1.23360.22541281872706872122.9343
2023-12-31Perceptive Advisors LLC1.08070.14741122958-1186512-51.3759
Total 68.205121.095970874111+10614783+15.0%

3.2. Funds holding Cogent Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28SPDR® S&P Biotech ETF6.1420.52265872565740801.2776
2024-02-29Vanguard Total Stock Mkt Idx Inv2.66930.0012255220500
2024-02-29Fidelity Select Biotechnology2.35080.32224769422476940
2023-12-31Eventide Healthcare & Life Sciences I2.33540.78772232968829683.859
2024-03-28iShares Russell 2000 ETF2.12450.020820312849810.0483
2024-02-29Fidelity Advisor Biotechnology I2.10770.7933201520081660068.1295
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.17190.00771120509-915-0.0816
2023-11-30MEDICAL BioHealth EUR Acc0.9021.007786239400
2024-01-31Fidelity Small Cap Index0.87540.015836984140481.7071
2024-03-31Direxion Daily S&P Biotech Bull 3X ETF0.73720.3793704860-4945-0.6967
2024-03-28iShares Biotechnology ETF0.66060.055663159500
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.52940.008550614988001.7694
2024-02-29Fidelity Extended Market Index0.44940.0078429653135473.2557
2024-03-28iShares Russell 2000 Growth ETF0.40320.0222385542-448-0.1161
2024-02-29DFA US Small Cap I0.38690.016736996900
2024-03-28iShares Russell 2000 Value ETF0.37520.0192358751-227-0.0632
2024-03-29Schwab US Small-Cap ETF™0.37350.014135716200
2024-02-29Franklin Biotechnology Discovery A0.35610.21463404483404480
2024-02-29DFA US Micro Cap I0.35020.0327334792-26197-7.257
2024-01-31Fidelity Advisor Small Cap I0.33780.07632300000
Total 25.63854.322724513724+3566434+14.5%

3.3. Insider Transactions

Insiders are holding 0.143% of the shares of Cogent Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-06-09Fairmount Funds Management LlcBUY80000012

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cogent Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.4340.005-8827%0.100-534%0.095-557%0.089-590%
Book Value Per Share--2.4812.725-9%2.533-2%1.657+50%1.269+96%
Current Ratio--7.0949.951-29%11.326-37%9.816-28%7.578-6%
Debt To Asset Ratio--0.1770.147+21%0.124+44%0.249-29%0.246-28%
Debt To Equity Ratio--0.2160.173+25%0.142+52%0.286-25%0.334-35%
Dividend Per Share----0%-0%-0%-0%
Eps---0.523-0.463-12%-0.337-36%-0.297-43%-0.233-56%
Free Cash Flow Per Share---0.427-0.376-12%-0.302-29%-0.202-53%-0.165-61%
Free Cash Flow To Equity Per Share---0.4270.017-2595%0.092-567%0.086-599%0.064-763%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---28.554--------
Intrinsic Value_10Y_min---24.099--------
Intrinsic Value_1Y_max---1.355--------
Intrinsic Value_1Y_min---1.330--------
Intrinsic Value_3Y_max---5.219--------
Intrinsic Value_3Y_min---4.960--------
Intrinsic Value_5Y_max---10.468--------
Intrinsic Value_5Y_min---9.617--------
Market Cap675434500.000+10%611008440.000993927845.000-39%1116804967.500-45%720862665.775-15%663942835.554-8%
Net Profit Margin----0%-0%-9.6900%-7.9180%
Operating Margin----0%-0%-12.0880%-9.6660%
Operating Ratio----0%-0%11.206-100%9.322-100%
Pb Ratio2.620+10%2.3703.565-34%4.281-45%3.490-32%6.618-64%
Pe Ratio-3.106-11%-2.810-5.406+92%-7.924+182%-6.203+121%-8.851+215%
Price Per Share6.500+10%5.8809.565-39%10.748-45%6.937-15%6.389-8%
Price To Free Cash Flow Ratio-3.804-11%-3.442-6.555+90%-8.773+155%-9.288+170%-11.200+225%
Price To Total Gains Ratio-14.978-11%-13.549-15.200+12%-27.554+103%-21.300+57%-28.093+107%
Quick Ratio--12.52914.707-15%13.836-9%11.200+12%8.762+43%
Return On Assets---0.173-0.143-18%-0.114-34%-0.130-25%-0.114-34%
Return On Equity---0.211-0.168-20%-0.130-38%-0.152-28%-0.147-30%
Total Gains Per Share---0.4340.005-8827%0.100-534%0.095-557%0.089-590%
Usd Book Value--257802000.000283172750.000-9%263231250.000-2%172173700.000+50%131861321.429+96%
Usd Book Value Change Per Share---0.4340.005-8827%0.100-534%0.095-557%0.089-590%
Usd Book Value Per Share--2.4812.725-9%2.533-2%1.657+50%1.269+96%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.523-0.463-12%-0.337-36%-0.297-43%-0.233-56%
Usd Free Cash Flow---44385000.000-39105000.000-12%-31375250.000-29%-20967850.000-53%-17125178.571-61%
Usd Free Cash Flow Per Share---0.427-0.376-12%-0.302-29%-0.202-53%-0.165-61%
Usd Free Cash Flow To Equity Per Share---0.4270.017-2595%0.092-567%0.086-599%0.064-763%
Usd Market Cap675434500.000+10%611008440.000993927845.000-39%1116804967.500-45%720862665.775-15%663942835.554-8%
Usd Price Per Share6.500+10%5.8809.565-39%10.748-45%6.937-15%6.389-8%
Usd Profit---54365000.000-46940000.000-14%-33160750.000-39%-24965900.000-54%-19976500.000-63%
Usd Revenue----0%-0%1518500.000-100%1730857.143-100%
Usd Total Gains Per Share---0.4340.005-8827%0.100-534%0.095-557%0.089-590%
 EOD+5 -3MRQTTM+3 -26YOY+3 -265Y+10 -2110Y+10 -21

4.2. Fundamental Score

Let's check the fundamental score of Cogent Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.106
Price to Book Ratio (EOD)Between0-12.620
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than112.529
Current Ratio (MRQ)Greater than17.094
Debt to Asset Ratio (MRQ)Less than10.177
Debt to Equity Ratio (MRQ)Less than10.216
Return on Equity (MRQ)Greater than0.15-0.211
Return on Assets (MRQ)Greater than0.05-0.173
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Cogent Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.208
Ma 20Greater thanMa 506.604
Ma 50Greater thanMa 1006.841
Ma 100Greater thanMa 2006.304
OpenGreater thanClose6.460
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Total Other Income Expense Net 4,1275234,650-4,3822683,9304,198-4,205-7



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets313,437
Total Liabilities55,635
Total Stockholder Equity257,802
 As reported
Total Liabilities 55,635
Total Stockholder Equity+ 257,802
Total Assets = 313,437

Assets

Total Assets313,437
Total Current Assets270,771
Long-term Assets42,666
Total Current Assets
Cash And Cash Equivalents 53,229
Short-term Investments 212,481
Other Current Assets 5,061
Total Current Assets  (as reported)270,771
Total Current Assets  (calculated)270,771
+/-0
Long-term Assets
Property Plant Equipment 30,342
Long Term Investments 7,460
Long-term Assets Other 4,864
Long-term Assets  (as reported)42,666
Long-term Assets  (calculated)42,666
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities38,168
Long-term Liabilities17,467
Total Stockholder Equity257,802
Total Current Liabilities
Short-term Debt 1,386
Accounts payable 10,655
Other Current Liabilities 441
Total Current Liabilities  (as reported)38,168
Total Current Liabilities  (calculated)12,482
+/- 25,686
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt17,467
Long-term Liabilities  (as reported)17,467
Long-term Liabilities  (calculated)17,467
+/-0
Total Stockholder Equity
Common Stock86
Retained Earnings -603,624
Accumulated Other Comprehensive Income 246
Other Stockholders Equity 801,059
Total Stockholder Equity (as reported)257,802
Total Stockholder Equity (calculated)197,767
+/- 60,035
Other
Capital Stock60,121
Cash and Short Term Investments 265,710
Common Stock Shares Outstanding 86,730
Current Deferred Revenue25,686
Liabilities and Stockholders Equity 313,437
Net Debt -34,376
Net Invested Capital 197,767
Net Working Capital 232,603
Property Plant and Equipment Gross 34,007
Short Long Term Debt Total 18,853



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
> Total Assets 
0
0
0
49,115
43,415
102,723
94,786
85,927
81,280
69,308
57,884
49,423
38,939
31,055
139,870
250,916
237,610
228,516
215,385
232,092
206,869
366,052
331,560
300,810
263,198
392,369
355,446
313,437
313,437355,446392,369263,198300,810331,560366,052206,869232,092215,385228,516237,610250,916139,87031,05538,93949,42357,88469,30881,28085,92794,786102,72343,41549,115000
   > Total Current Assets 
0
0
0
42,379
35,227
97,111
89,499
81,002
69,900
58,598
45,882
40,591
31,185
23,949
129,420
244,912
232,069
221,350
207,504
222,633
194,733
330,675
296,417
264,966
226,270
334,519
312,835
270,771
270,771312,835334,519226,270264,966296,417330,675194,733222,633207,504221,350232,069244,912129,42023,94931,18540,59145,88258,59869,90081,00289,49997,11135,22742,379000
       Cash And Cash Equivalents 
0
0
0
28,270
25,704
46,732
49,296
55,671
59,114
55,863
45,882
37,424
29,604
21,342
129,420
242,190
230,739
218,105
202,888
219,684
191,047
325,562
140,568
139,886
160,698
214,317
86,810
53,229
53,22986,810214,317160,698139,886140,568325,562191,047219,684202,888218,105230,739242,190129,42021,34229,60437,42445,88255,86359,11455,67149,29646,73225,70428,270000
       Short-term Investments 
0
0
0
12,691
6,696
47,715
37,824
22,923
7,989
0
0
0
0
0
0
0
0
0
0
0
0
0
148,526
119,390
59,566
115,082
192,231
212,481
212,481192,231115,08259,566119,390148,52600000000000007,98922,92337,82447,7156,69612,691000
       Net Receivables 
0
0
0
830
1,601
1,202
1,419
1,668
2,040
1,492
880
2,000
0
0
0
0
0
0
0
0
0
0
4,768
0
4,775
4,775
0
0
004,7754,77504,76800000000002,0008801,4922,0401,6681,4191,2021,601830000
       Other Current Assets 
0
0
0
513
1,176
1,412
960
740
757
1,243
1,216
1,167
1,581
2,607
3,996
2,722
1,330
3,245
4,616
2,949
3,686
5,113
7,323
5,690
4,751
5,120
6,912
5,061
5,0616,9125,1204,7515,6907,3235,1133,6862,9494,6163,2451,3302,7223,9962,6071,5811,1671,2161,2437577409601,4121,176513000
   > Long-term Assets 
0
0
0
6,736
8,188
5,612
5,287
4,925
11,380
10,710
23,548
8,832
7,754
7,106
10,450
6,004
5,541
7,166
7,881
9,459
12,136
35,377
35,143
35,844
36,928
57,850
69,493
42,666
42,66669,49357,85036,92835,84435,14335,37712,1369,4597,8817,1665,5416,00410,4507,1067,7548,83223,54810,71011,3804,9255,2875,6128,1886,736000
       Property Plant Equipment 
0
0
0
4,108
3,902
3,938
3,613
3,251
9,279
8,609
7,804
7,150
6,499
5,851
5,199
4,749
4,286
3,941
4,590
4,477
5,275
30,482
30,375
31,099
32,153
31,563
30,837
30,342
30,34230,83731,56332,15331,09930,37530,4825,2754,4774,5903,9414,2864,7495,1995,8516,4997,1507,8048,6099,2793,2513,6133,9383,9024,108000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,512
0
7,460
7,460021,5120000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
-11,546
0
0
0
6,301
5,870
1,255
3,225
3,291
4,982
6,861
4,895
4,768
4,745
0
4,775
-26,882
0
0-26,8824,77504,7454,7684,8956,8614,9823,2913,2251,2555,8706,301000-11,5460000000000
> Total Liabilities 
0
0
0
20,810
27,517
26,048
27,255
25,693
31,990
29,550
29,261
17,661
13,237
11,814
162,044
16,249
10,847
15,712
18,147
17,908
19,006
46,667
41,618
45,075
39,635
43,941
52,548
55,635
55,63552,54843,94139,63545,07541,61846,66719,00617,90818,14715,71210,84716,249162,04411,81413,23717,66129,26129,55031,99025,69327,25526,04827,51720,810000
   > Total Current Liabilities 
0
0
0
11,190
22,960
24,814
26,384
24,945
26,345
24,307
24,430
13,248
9,250
8,269
20,121
13,094
8,242
13,681
16,709
17,077
17,879
27,658
23,551
26,849
21,120
25,757
34,719
38,168
38,16834,71925,75721,12026,84923,55127,65817,87917,07716,70913,6818,24213,09420,1218,2699,25013,24824,43024,30726,34524,94526,38424,81422,96011,190000
       Short-term Debt 
0
0
0
2,773
0
0
0
3,798
1,507
1,543
1,581
1,619
1,658
1,698
1,988
2,052
2,117
2,184
2,253
2,324
2,395
9,057
2,014
1,423
947
1,177
1,344
1,386
1,3861,3441,1779471,4232,0149,0572,3952,3242,2532,1842,1172,0521,9881,6981,6581,6191,5811,5431,5073,7980002,773000
       Accounts payable 
0
0
0
1,346
3,083
1,664
803
1,519
1,836
1,660
1,594
3,183
628
632
639
732
315
1,992
4,349
3,483
4,015
3,492
4,093
5,842
4,172
7,161
9,868
10,655
10,6559,8687,1614,1725,8424,0933,4924,0153,4834,3491,9923157326396326283,1831,5941,6601,8361,5198031,6643,0831,346000
       Other Current Liabilities 
0
0
0
180
2,358
2,787
5,495
1,679
6,067
5,929
6,538
7,131
6,123
5,627
5,535
6,515
2,750
6,445
7,047
3,295
8,409
15,109
17,444
17,884
16,001
496
23,507
441
44123,50749616,00117,88417,44415,1098,4093,2957,0476,4452,7506,5155,5355,6276,1237,1316,5385,9296,0671,6795,4952,7872,358180000
   > Long-term Liabilities 
0
0
0
9,620
4,557
1,234
871
748
5,645
5,243
4,831
4,413
3,987
3,545
3,691
3,155
2,605
2,031
1,438
831
1,127
19,009
18,067
18,226
18,515
18,184
17,829
17,467
17,46717,82918,18418,51518,22618,06719,0091,1278311,4382,0312,6053,1553,6913,5453,9874,4134,8315,2435,6457488711,2344,5579,620000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
94,681
85,400
85,400
0
0
0
0
0
0
0
0
0
00000000085,40085,40094,6810000000000000000
> Total Stockholder Equity
0
0
0
28,305
15,898
76,675
67,531
60,234
49,290
39,758
28,623
31,762
25,702
19,241
-22,174
234,667
226,763
212,804
197,238
214,184
187,863
319,385
289,942
255,735
223,563
348,428
302,898
257,802
257,802302,898348,428223,563255,735289,942319,385187,863214,184197,238212,804226,763234,667-22,17419,24125,70231,76228,62339,75849,29060,23467,53176,67515,89828,305000
   Common Stock
0
0
0
10
10
30
30
30
30
30
30
30
31
32
11
32
37
40
40
44
46
66
70
70
71
85
86
86
86868571707066464440403732113231303030303030301010000
   Retained Earnings Total Equity00-493,877-449,801-411,214-371,596-336,534-301,607-270,973-246,061-226,977-210,428-198,700000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-16
-7
-13
-24
-12
-2
0
0
-4,631
0
0
49,130
0
0
0
0
-85,400
0
0
-163
-104
16
-97
-172
246
246-172-9716-104-16300-85,400000049,13000-4,63100-2-12-24-13-7-16000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
322,454
342,473
354,341
357,859
399,713
411,024
584,453
595,801
601,153
610,967
780,007
0
0
00780,007610,967601,153595,801584,453411,024399,713357,859354,341342,473322,454000000000000000
   Treasury Stock0000000000000000000000000000
   Other Stockholders Equity 
0
0
0
2,499
2,990
47,220
56,192
152,275
153,012
153,994
154,782
155,624
155,657
156,588
-22,185
322,454
342,473
354,341
357,859
485,113
411,024
584,453
595,801
601,153
610,967
780,007
792,208
801,059
801,059792,208780,007610,967601,153595,801584,453411,024485,113357,859354,341342,473322,454-22,185156,588155,657155,624154,782153,994153,012152,27556,19247,2202,9902,499000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-3,588
Gross Profit-3,588-3,588
 
Operating Income (+$)
Gross Profit-3,588
Operating Expense-204,542
Operating Income-208,130-208,130
 
Operating Expense (+$)
Research Development170,167
Selling General Administrative34,375
Selling And Marketing Expenses0
Operating Expense204,542204,542
 
Net Interest Income (+$)
Interest Income11,317
Interest Expense-0
Other Finance Cost-0
Net Interest Income11,317
 
Pretax Income (+$)
Operating Income-208,130
Net Interest Income11,317
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-192,410-223,850
EBIT - interestExpense = -208,130
-192,410
-192,410
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-208,130-192,410
Earnings Before Interest and Taxes (EBITDA)-204,542
 
After tax Income (+$)
Income Before Tax-192,410
Tax Provision-0
Net Income From Continuing Ops-177,663-192,410
Net Income-192,410
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses208,130
Total Other Income/Expenses Net15,720-11,317
 

Technical Analysis of Cogent Biosciences Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cogent Biosciences Inc. The general trend of Cogent Biosciences Inc is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cogent Biosciences Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cogent Biosciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 7.18 < 7.38 < 9.23.

The bearish price targets are: 5.73 > 5.37 > 4.28.

Tweet this
Cogent Biosciences Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cogent Biosciences Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cogent Biosciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cogent Biosciences Inc. The current macd is -0.02593773.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cogent Biosciences Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cogent Biosciences Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cogent Biosciences Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Cogent Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartCogent Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cogent Biosciences Inc. The current adx is 15.45.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cogent Biosciences Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Cogent Biosciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cogent Biosciences Inc. The current sar is 6.255.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Cogent Biosciences Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cogent Biosciences Inc. The current rsi is 47.21. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Cogent Biosciences Inc Daily Relative Strength Index (RSI) ChartCogent Biosciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cogent Biosciences Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cogent Biosciences Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Cogent Biosciences Inc Daily Stochastic Oscillator ChartCogent Biosciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cogent Biosciences Inc. The current cci is -16.92156501.

Cogent Biosciences Inc Daily Commodity Channel Index (CCI) ChartCogent Biosciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cogent Biosciences Inc. The current cmo is -9.56780317.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Cogent Biosciences Inc Daily Chande Momentum Oscillator (CMO) ChartCogent Biosciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cogent Biosciences Inc. The current willr is -48.92086331.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cogent Biosciences Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Cogent Biosciences Inc Daily Williams %R ChartCogent Biosciences Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cogent Biosciences Inc.

Cogent Biosciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cogent Biosciences Inc. The current atr is 0.50276345.

Cogent Biosciences Inc Daily Average True Range (ATR) ChartCogent Biosciences Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cogent Biosciences Inc. The current obv is 144,949,993.

Cogent Biosciences Inc Daily On-Balance Volume (OBV) ChartCogent Biosciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cogent Biosciences Inc. The current mfi is 56.80.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Cogent Biosciences Inc Daily Money Flow Index (MFI) ChartCogent Biosciences Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cogent Biosciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-07MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-14MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.

6.3. Candlestick Patterns

Cogent Biosciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cogent Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.208
Ma 20Greater thanMa 506.604
Ma 50Greater thanMa 1006.841
Ma 100Greater thanMa 2006.304
OpenGreater thanClose6.460
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cogent Biosciences Inc with someone you think should read this too:
  • Are you bullish or bearish on Cogent Biosciences Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cogent Biosciences Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cogent Biosciences Inc

I send you an email if I find something interesting about Cogent Biosciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cogent Biosciences Inc.

Receive notifications about Cogent Biosciences Inc in your mailbox!